Executive Assistant

Epicrispr awarded $8M CIRM grant for FSHD Clinical Trial. CIRM's support for Epicrispr Biotechnologies has a defined clinical destination: the study already evaluating EPI-321 in people with facioscapulohumeral muscular dystrophy, or FSHD. The South San Francisco biotechnology company announced an $8M grant on October 19, 2026, bringing public backing to the work of following an experimental gene-regulating medicine through its first human study. The award supports a program intended to suppress inappropriate activity of DUX4, a gene implicated in progressive muscle damage. EPI-321 is designed for a single administration, while its developers must observe safety, biological activity and patient outcomes over time. That relationship between a brief treatment encounter and a much longer investigation gives the financing its practical significance. The California Institute for Regenerative Medicine approved the grant on September 25, and its award database currently labels it pre-active. Epicrispr's company announcement and CIRM's approval are separate milestones; neither establishes when cash reaches the company. The grant also sits alongside a distinct $90M Series C announced in August, rather than replacing that financing or creating a new combined equity round. What the $8M CIRM grant supports. CIRM's award record identifies the project as the first-in-human EPI-321 trial and assigns it grant number CLIN2-20392. The agency's Clinical Trial Stage Projects program is supporting clinical investigation at a point when a promising biological approach has become a responsibility to actual participants. The funding's scope is specific enough to keep the story grounded: continued work on this study. The September board announcement also lists the $8M award to Epicrispr. The company's October announcement describes support for ongoing clinical development, without publishing a disbursement schedule. There is no verified valuation, ownership change or new venture syndicate attached to this grant, and those blanks should stay blank. Epicrispr has attracted support for different jobs within the same company. Private investors can finance a platform, a pipeline and organizational capacity, while a grant directs support toward a particular investigation. In Epicrispr's case, both forms of backing meet at EPI-321, where continued observation helps determine how the underlying science translates into a medicine people can use. How EPI-321 approaches FSHD. Epicrispr's scientific founder, Lei Stanley Qi, helped develop tools for regulating gene expression. CEO Amber Salzman leads the company as it carries that scientific foundation into therapeutic development. Its Gene Expression Modulation System, or GEMS, combines a DNA-binding component, a guide RNA and proteins that influence gene activity, according to the company's platform description. EPI-321 applies gene regulation to FSHD, where inappropriate DUX4 expression contributes to muscle degeneration. The study protocol describes an AAVrh74-delivered, noncutting epigenetic editor that targets the D4Z4 region associated with DUX4 regulation. The intended effect is suppression of harmful gene activity without changing the underlying DNA sequence; the duration and clinical value of that effect are subjects of investigation. This approach gives the company several connected development jobs. A construct has to reach the intended tissue, produce the intended biological response and be assessed for effects that emerge over time. Explaining only the gene target would leave out much of the work the clinical organization has inherited from the laboratory. The company has chosen a program in which delivery, measurement and sustained follow-up all belong inside the same account of progress. Reading the early clinical evidence. The ClinicalTrials.gov record for NCT06907875 describes a Phase 1/2, open-label, nonrandomized dose-escalation study, with estimated enrollment of 12 across 2 dose cohorts. Its primary outcome concerns adverse events, while other measures examine biological activity. Participants receive one intravenous administration and are followed over an extended period, making the study a continuing relationship between the company, investigators and patients. In its October 5 clinical update, Epicrispr reported increases in lean muscle volume and strength among the first 6 patients with six-month observations. The comparisons used external natural-history data and modeled digital twins. Those are company-reported exploratory findings from an early study, with a different evidentiary basis from a randomized concurrent control group. For anyone evaluating the program, muscle imaging, strength testing and safety observations need to be read together. A numerical change becomes more useful when its measurement method, comparator and follow-up interval remain attached to it. The grant supports a setting where that record can keep developing, rather than supplying an answer about eventual approval, treatment durability or commercial adoption. Public funding within a privately financed platform. Epicrispr's August 11 Series C brought in $90M, co-led by Octagon Capital and Janus Henderson Investors. The company said that financing would support EPI-321, additional programmable epigenetic medicines, its platform and manufacturing capabilities. Those broader uses help explain why the separate CIRM grant deserves its own description rather than being folded into a larger capital headline. EPI-321 also gives Epicrispr a clinical setting in which to learn how its platform behaves. Findings from a lead candidate can inform decisions about delivery, assay selection, development priorities and the questions worth carrying into another study. That possibility gives clinical work significance beyond a single product, although success in one indication would still leave other programs with their own evidence requirements. The wider biotechnology financing landscape contains companies at quite different points in that process. DevCuration's coverage of Estuary Biotherapeutics' kidney gene-therapy financing offers another view of capital organized around delivery and development. For Epicrispr, the immediate work remains with people already participating in EPI-321's study. The company expects twelve-month data from all study patients in the second half of 2027, extending the record its clinical team and future development decisions will have to draw on.

Epicrispr Biotechnologies receives $8M in grant. October 19, 2026 Epicrispr Biotechnologies, a San Francisco, CA-based company developing epigenetic therapies, received an $8M grant from the California Institute for Regenerative Medicine (CIRM). The company intends to use the funds to support the ongoing first-in-human clinical development of EPI-321, its lead investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). Led by CEO Amber Salzman, Ph.D., Epicrispr Biotechnologies is a biotechnology company pioneering gene-modulating therapies, leading with treatments for neuromuscular diseases. Their platform, the proprietary gene expression modulation system (GEMS), enables precise and durable epigenetic modulation of gene expression without altering the underlying DNA sequence. Don't just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week - in our structured Master Database (XML) + Weekly Intelligence PDF. [Access FinSMEs Intelligence Hub] 19/10/2026